Abstract 4864: ALK inhibitors downregulate the expression of death receptor 4 in ALK-mutant NSCLC cells via facilitating Fra-1 and c-Jun degradation and subsequent AP-1 suppression
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-4864
Abstract: The successful treatment of patients with advanced non-small cell lung cancer (NSCLC) harboring chromosomal rearrangements of anaplastic lymphoma kinase (ALK) with ALK tyrosine kinase inhibitors (ALK-TKIs) represents a promising targeted therapy. As a result, various… read more here.
Keywords: dr4; fra jun; expression; alk ... See more keywords